Blue Cross Blue Shield Association and Illumina are joining forces to assess the availability and clinical understanding of DNA sequencing technologies, genetic testing and precision medicine.
Illumina, a provider of DNA sequencing and array-based technologies, will work with the BCBS Association to analyze trends in DNA sequencing and genomic testing across the country to identify areas where access to these services is lacking.
Additionally, the organizations will offer precision medicine-focused educational programs to healthcare providers in areas where people would most benefit from genetic medicine.
"Through our partnership with Illumina, we'll have a better understanding of how precision medicine is being used so we can avoid inequities by ensuring all Americans have access to these lifesaving treatments that are tailored to their individual health needs," said Trent Haywood, MD, senior vice president and CMO for the Blue Cross Blue Shield Association.